InVivo Therapeutics Calls for Papers for 2nd Annual Langer Summit on Neurotrauma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced the 2nd Annual Langer Summit on Neurotrauma, taking place on Cape Cod in North Falmouth, MA on July 12 14, 2013. The Company is inviting papers in the fields of neurotrauma and SCI, and will announce the recipient of a $50,000 grant that will be given to a researcher developing novel biomaterial treatments for neurotrauma at the Summit. The award is intended to stimulate innovation and cutting-edge ideas in the fields of neuroprotection and regeneration utilizing biomaterials.

If you are a researcher in these fields, please submit your paper to InVivo Therapeutics by April 15, 2013. Your submission will be evaluated by Robert S. Langer, ScD and a panel of experts. The top author will be invited to present at the invitation-only event.

Well continue what we started at the 2012 Summit, fostering a productive exchange of ideas between InVivo scientists and neurotrauma researchers with the objective of furthering the development of treatments for SCI and other neurotrauma conditions, said InVivo CEO Frank Reynolds. Since the last Summit, weve been focused on advancing our scaffolding device into a first-in-man clinical trial. By the 2013 Summit, we expect to have the clinical study underway, so the Summit will focus on our growing portfolio of hydrogel technologies.

About the Event

The Langer Summit on Neurotrauma was first held in 2012 and brought together researchers from across the world to address the challenges faced by interventions developed for spinal cord injury and other neurological conditions. The Summit is chaired by InVivo Therapeutics co-founder Robert S. Langer, ScD, the David H. Koch Institute Professor at the Massachusetts Institute of Technology. At this years event, participants will focus on InVivos expanding pipeline of 510(k) devices as well as recent innovations and their translation to the clinic.

Submissions

Authors are asked to submit papers in PDF format to Lauren Mitarotondo, Vice President of Operations, at lmitarotondo@invivotherapeutics.com.

Format: 8x 11 (letter size), 1-inch margins, single line spacing, full justification, 11pt Times New Roman, include page numbers. Submissions are limited to 1 page of abstract and 2 pages of body text including tables, figures and references.

Abstract: The abstract should be less than page, preceded by Abstract: in bold.

See the article here:
InVivo Therapeutics Calls for Papers for 2nd Annual Langer Summit on Neurotrauma